A four-part study to evaluate the safety, tolerability, and efficacy of enoxaparin for inhalation, alone and in combination with N-acetylcysteine in healthy volunteers and hospitalised COVID-19 patients
Latest Information Update: 04 Aug 2022
Price :
$35 *
At a glance
- Drugs AT-H201 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Atossa Therapeutics
- 28 Jul 2022 According to an Atossa Therapeutics media release, part D of the study will not be conducted because of the rapidly shifting COVID-19 treatment landscape and the introduction of effective vaccines limiting hospitalizations.
- 28 Jul 2022 According to an Atossa Therapeutics media release, the company has completed dosing participants in Part C of the trial in Australia.
- 20 Apr 2022 According to an Atossa Therapeutics media release, Parts A, B and C of the study are being conducted by Avance Clinical Pty Ltd and the company commencing parts C and D of the study is subject to additional approvals from the Australian Human Research Ethics Committee.